Thought Leadership

Journal Article
Regulators are tightening their scrutiny of the trial master file (TMF), placing the onus on companies to be ready for evaluation. Inspection-readiness should be embedded from the beginning, rather than a reaction to a notice of an inspection.
Journal Article
The life sciences industry is shifting its dealmaking focus from high-cost acquisitions to smaller and more targeted deals. Even big pharmaceutical companies are moving away from mega mergers, which are a huge undertaking, and switching toward early-stage assets and smaller deals that allow them to manage risks and large investments.
Scroll to Top